Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

mayne pharma commercial llc - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 60 mg - doryx mpc is indicated for treatment of rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae . doryx mpc is indicated for treatment of the following sexually transmitted infections: - uncomplicated urethral, endocervical or rectal infections in adults caused by chlamydia trachomatis. - nongonococcal urethritis caused by ureaplasma urealyticum . - lymphogranuloma venereum caused by chlamydia trachomatis . - granuloma inguinale caused by klebsiella granulomatis . - uncomplicated gonorrhea caused by neisseria gonorrhoeae . - chancroid caused by haemophilus ducreyi . doryx mpc is indicated for treatment of the following respiratory tract infections: - respiratory tract infections caused by mycoplasma pneumoniae . - psittacosis (ornithosis) caused by chlamydophila psittaci . - because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. - doxycycline is indicated for treatment of infections caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug: – respiratory tract infections caused by haemophilus influenzae . – respiratory tract infections caused by klebsiella species. – upper respiratory infections caused by streptococcus pneumoniae . doryx mpc is indicated for treatment of the following specific bacterial infections: - relapsing fever due to borrelia recurrentis . - plague due to yersinia pestis . - tularemia due to francisella tularensis . - cholera caused by vibrio cholerae . - campylobacter fetus infections caused by campylobacter fetus . - brucellosis due to brucella species (in conjunction with streptomycin). - bartonellosis due to bartonella bacilliformis . because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. doryx mpc is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug: - escherichia coli - enterobacter aerogenes - shigella species - acinetobacter species - urinary tract infections caused by klebsiella species. doryx mpc is indicated for treatment of the following ophthalmic infections: - trachoma caused by chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. - inclusion conjunctivitis caused by chlamydia trachomatis . doryx mpc is indicated for treatment of anthrax due to bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis . doryx mpc is indicated as an alternative treatment for the following selected infections when penicillin is contraindicated: - syphilis caused by treponema pallidum . - yaws caused by treponema pallidum subspecies pertenue . - listeriosis due to listeria monocytogenes . - vincent's infection caused by fusobacterium fusiforme. - actinomycosis caused by actinomyces israelii . - infections caused by clostridium species. in acute intestinal amebiasis, doryx mpc may be a useful adjunct to amebicides. in severe acne, doryx mpc may be useful adjunctive therapy. doryx mpc is indicated for the prophylaxis of malaria due to plasmodium falciparum in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains [see dosage and administration (2.2) and patient counseling information (17) ]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of doryx mpc and other antibacterial drugs, doryx mpc should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doryx mpc is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. risk summary there are no adequate studies on the use of doxycycline in pregnant women. the vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. there are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of anthrax exposure. an expert review of published data on experiences with doxycycline use during pregnancy by teris - the teratogen information system - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.1 in the u.s. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively [see data ]. clinical considerations embryo/fetal risk results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). evidence of embryotoxicity also has been noted in animals treated early in pregnancy. if any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus. [see warnings and precautions (5.1, 5.6) ]. data human data a case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline. this association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation), with the exception of a marginal relationship with neural tube defect based on only two-exposed cases.2 a small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. all mothers reported their exposed infants were normal at 1 year of age.3 risk summary tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known. short-term use by lactating women is not contraindicated. the effects of prolonged exposure to doxycycline on breast milk production and breast fed neonates, infants and children are unknown.4 the developmental and health benefits of breast feeding should be considered along with the mother's clinical need for doryx mpc and any potential adverse effects on the breast fed child from doryx mpc or from the underlying maternal condition [see warnings and precautions (5.1, 5.6) ]. because of the effects of drugs of the tetracycline-class on tooth development and growth, use doryx mpc in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, rocky mountain spotted fever), particularly when there are no alternative therapies [see warnings and precautions (5.1, 5.6) and dosage and administration (2.1, 2.4) ]. clinical studies of doryx mpc did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. doryx mpc tablets each contain less than 10 mg of sodium.

Ηνωμένες Πολιτείες - Αγγλικά - myHealthbox

bayer ag -

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - insulin aspart - solution for injection - 100unit/1ml

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

gold lite pte ltd - general hospital - the argus mpc central station is designed for the monitoring of vital parameters such as ecg, spo2, etco2, non invasive blood pressure (nibp), invasive blood pressure (ibp), temperature and respiration of up to 64 patients. the argus lcx patient monitoring unit is designed for the monitoring of vital parameters such as ecg, spo2, etco2, non invasive blood pressure (nibp), invasive blood pressure (ibp), temperature and respiration of a patient.

Ινδία - Αγγλικά - Central Drugs Standard Control Organization

oregan lab. - cap - 10

Ινδία - Αγγλικά - Central Drugs Standard Control Organization

jawa ph. - eye oint - 5gms

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - citric acid monohydrate; potassium citrate -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

paragon medical pty ltd trading as lr instruments richards medical -

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

kingston medical supplies (private) limited - general & plastic surgery - intended for monopolar/bipolar cut and coagulation/microcoagulation in: gynaecology, dermatology, plastic surgery, dental and maxillo-facial surgery, angiology, general surgery, oral, gastroenterology